Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea‐based cohort study
International Journal of Gynecology & Obstetrics · 2023
DOI: 10.1002/ijgo.14753 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2023. Verfasst von Jin-Sung Yuk. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Progestins, Endometrial Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Objective
To determine the risk of endometrial cancer according to the types of menopausal hormones used.
Methods
This retrospective cohort study recruited postmenopausal women older than 40 years from 2003 to 2011, utilizing data from the Korean national health insurance system from 2002 to 2019. The menopausal hormone therapy (MHT) group consisted of women who had been prescribed MHT for greater than 6 months between 2003 and 2011. The non‐MHT group consisted of women who had never used menopausal hormones between 2003 and 2011.
Results
A non‐MHT group of 1 000 550 women and a MHT group of 353 025 women were chosen. In comparison to never‐users, the risk of endometrial cancer was not higher in women who reported last using tibolone (adjusted hazard ratio [aHR] 1.08, 95% confidence interval [CI] 0.96–1.2), combined estrogen plus progestin by the manufacturer (aHR 0.83, 0.72–0.96), combined estrogen plus progestin by the physician (aHR 0.88, 0.7–1.12), and transdermal estrogen (aHR 1.13, 0.36–3.52).
Conclusions
Tibolone, combined estrogen plus progestin by the physician, and transdermal estrogen do not affect the risk of endometrial cancer. The combination of estrogen plus progestin by the manufacturer decreases the risk of endometrial cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Republic of Korea.
ORCID-Profile: Jin-Sung Yuk
Zitieren
APA
Yuk, J. S. (2023). Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea‐based cohort study. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.14753
Vancouver
Yuk JS. Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea‐based cohort study. International Journal of Gynecology & Obstetrics. 2023. doi:10.1002/ijgo.14753
BibTeX
@article{Yuk2023,
author = {Yuk, Jin-Sung},
title = {Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea‐based cohort study},
journal = {International Journal of Gynecology & Obstetrics},
year = {2023},
doi = {10.1002/ijgo.14753}
}
EUVIMED